BIOMAT Database Logo BIOMAT Database Logo

Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. 1985

P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen

UI MeSH Term Description Entries
D007008 Hypokalemia Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed) Hypopotassemia,Hypokalemias,Hypopotassemias
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007516 Adenoma, Islet Cell A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM. Islet Cell Tumor,Islet of Langerhans Tumor,Nesidioblastoma,Pancreatic Islet Cell Tumors,Island Cell Tumor,Adenomas, Islet Cell,Island Cell Tumors,Islet Cell Adenoma,Islet Cell Adenomas,Islet Cell Tumors,Langerhans Tumor Islet,Nesidioblastomas,Tumor Islet, Langerhans,Tumor, Island Cell,Tumor, Islet Cell,Tumors, Island Cell,Tumors, Islet Cell
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D009037 Motilin A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect.
D009496 Neurotensin A biologically active tridecapeptide isolated from the hypothalamus. It has been shown to induce hypotension in the rat, to stimulate contraction of guinea pig ileum and rat uterus, and to cause relaxation of rat duodenum. There is also evidence that it acts as both a peripheral and a central nervous system neurotransmitter.
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010191 Pancreatic Polypeptide A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the ISLETS OF LANGERHANS and adjacent to cells containing SOMATOSTATIN and GLUCAGON. Pancreatic polypeptide (PP), when administered peripherally, can suppress gastric secretion, gastric emptying, pancreatic enzyme secretion, and appetite. A lack of pancreatic polypeptide (PP) has been associated with OBESITY in rats and mice. Pancreatic Polypeptide (PP),Pancreatic Polypeptide Hormone,Pancreatic Prohormone
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas

Related Publications

P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
The effect of long acting somatostatin analogue SMS 201-995 in acromegaly.
July 1987, The Korean journal of internal medicine,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
October 1988, Endocrinologia japonica,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
The long-acting somatostatin analogue SMS 201-995 causes malabsorption.
December 1989, Scandinavian journal of gastroenterology,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201-995.
October 1987, Clinical endocrinology,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
December 1986, Annals of internal medicine,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
[Somatostatin analogue (SMS 201-995)].
February 1989, Harefuah,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995.
May 1988, Scandinavian journal of gastroenterology,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
Pseudopancreatic cholera syndrome: effect of a synthetic somatostatin analogue, SMS 201-995.
May 1987, The American journal of medicine,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
Hypoglycaemia in acromegalic patients treated with long acting somatostatin analogue (SMS 201-995).
May 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
P N Maton, and T M O'Dorisio, and B A Howe, and K E McArthur, and J M Howard, and J A Cherner, and T B Malarkey, and M J Collen, and J D Gardner, and R T Jensen
[Successful therapy of VIPoma with the long-acting somatostatin analogue SMS 201-995].
January 1988, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Copied contents to your clipboard!